AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30170579 — intervention group
Group type: EXPERIMENTAL
Intervention: BTI320 4 g (low dose)
Number of subjects: 60
Study 30170579 — intervention group
Group type: EXPERIMENTAL
Intervention: BTI320 8 g (high dose)
Number of subjects: 60
Study 30170579 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 29071948 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) therapy, treated by EA stimulation of bilateral Neiting (ST 44), Fenglong (ST 40), Zusanli (ST 36), Huaroumen (ST 24), Tianshu (ST 25), Wailing (ST 26), Shuidao (ST 28), Fujie (SP 14), Daheng (SP 13) for 25 min, once every other day, 3 times per week for 3 months.
Number of subjects: 30
Study 29071948 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment for weight reduction).
Number of subjects: 30
Study 25170938 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir (RAL) with ritonavir-boosted darunavir (DRV/r)
Number of subjects: 85
Study 25170938 — intervention group
Group type: COMPARATOR
Intervention: Tenofovir/emtricitabine (TDF/FTC) with ritonavir-boosted darunavir (DRV/r)
Number of subjects: 85
Study 25170938 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir (RAL)
Number of subjects: 85
Study 25170938 — intervention group
Group type: COMPARATOR
Intervention: Tenofovir/emtricitabine (TDF/FTC)
Number of subjects: 85
Study 21868752 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 IU recombinant human follicle‐stimulating hormone (rFSH) administered on alternate days for 90 days
Number of subjects: 129
Study 21868752 — intervention group
Group type: COMPARATOR
Intervention: Nonantioxidant vitamin supplements
Number of subjects: 129
Study 21868752 — intervention group
Group type: EXPERIMENTAL
Intervention: rFSH treatment in patients with high basal DFI values (>15%)
Number of subjects: 129
Study 21868752 — intervention group
Group type: COMPARATOR
Intervention: Vitamin supplements in patients with high basal DFI values (>15%)
Number of subjects: 129
Study 20620692 — intervention group
Group type: EXPERIMENTAL
Intervention: Sono-thrombolysis
Number of subjects: 32
Study 20620692 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of sono-thrombolysis and IVT
Number of subjects: 32
Study 20620692 — intervention group
Group type: EXPERIMENTAL
Intervention: Sono-thrombolysis alone
Number of subjects: 32
Study 20620692 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (control group)
Number of subjects: 32
Study 17443649 — intervention group
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel 10 mg/m2
Number of subjects: 23
Study 17443649 — intervention group
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel 30 mg/m2
Number of subjects: 23
Study 17443649 — intervention group
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel 70 mg/m2
Number of subjects: 23
Study 17443649 — intervention group
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel 100 mg/m2
Number of subjects: 23
Study 17443649 — intervention group
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel (all doses)
Number of subjects: 23
Study 15267184 — intervention group
Group type: EXPERIMENTAL
Intervention: Somnoguard® mandibular advancement device (MAD)
Number of subjects: 20
Study 15267184 — intervention group
Group type: EXPERIMENTAL
Intervention: Somnoguard® MAD
Number of subjects: 20
Study 12097457 — intervention group
Group type: EXPERIMENTAL
Intervention: Sestamibi
Number of subjects: 158
Study 12097457 — intervention group
Group type: EXPERIMENTAL
Intervention: MDP
Number of subjects: 158
Study 12097457 — intervention group
Group type: EXPERIMENTAL
Intervention: DMSA-V
Number of subjects: 158
Study 10233320 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracutaneous injections of botulinum A toxin (200 mouse units)
Number of subjects: 13
Study 10233320 — intervention group
Group type: COMPARATOR
Intervention: Sterile saline (placebo)
Number of subjects: 13
Study 7846789 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous and/or intracoronary thrombolysis (52 patients)
Number of subjects: 63
Study 7846789 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment (placebo, 11 patients)
Number of subjects: 63
Study 7846789 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous thrombolysis
Number of subjects: 63
Study 2192212 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct reconstruction of the esophagus
Number of subjects: 95
Study 2192212 — intervention group
Group type: COMPARATOR
Intervention: Reconstruction 48-72 h after esophagectomy
Number of subjects: 95
Study 2192212 — intervention group
Group type: COMPARATOR
Intervention: Transmediastinal esophagectomy with direct reconstruction
Number of subjects: 95
Study 28194 — intervention group
Group type: EXPERIMENTAL
Intervention: d‐amphetamine (10 mg)
Number of subjects: 0
Study 28194 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefopam (90 mg)
Number of subjects: 0
Study 28194 — intervention group
Group type: COMPARATOR
Intervention: Caffeine (300 mg)
Number of subjects: 0
Study 28194 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29554338 — intervention group
Group type: EXPERIMENTAL
Intervention: Model OA consultation
Number of subjects: 0
Study 29554338 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 27396241 — intervention group
Group type: EXPERIMENTAL
Intervention: linagliptin (5mg, monotherapy or combination therapy)
Number of subjects: 723
Study 27396241 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 723
Study 24342768 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous application of 50 μg CCK-4
Number of subjects: 30
Study 24342768 — intervention group
Group type: EXPERIMENTAL
Intervention: CCK-4 application
Number of subjects: 30
Study 23147984 — intervention group
Group type: EXPERIMENTAL
Intervention: 35 Hz NMES
Number of subjects: 20
Study 23147984 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 Hz NMES
Number of subjects: 20
Study 20085630 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone (0.3 ppm for 2 hours)
Number of subjects: 23
Study 19033610 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.6% carbohydrate plus 1% amino acids (AA)
Number of subjects: 12
Study 19033610 — intervention group
Group type: COMPARATOR
Intervention: 4.6% carbohydrate‐only (CHO)
Number of subjects: 12
Study 16179769 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi‐Cervical Unit (MCU)
Number of subjects: 32
Study 16179769 — intervention group
Group type: EXPERIMENTAL
Intervention: Thera‐Band tubing (THER)
Number of subjects: 32
Study 16179769 — intervention group
Group type: COMPARATOR
Intervention: Control (CTRL)
Number of subjects: 32
Study 11451319 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg ketoconazole daily for 3 months
Number of subjects: 29
Study 11451319 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 29
Study 9581210 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline
Number of subjects: 50
Study 9581210 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 8001356 — intervention group
Group type: EXPERIMENTAL
Intervention: High-energy fast neutrons
Number of subjects: 10
Study 8001356 — intervention group
Group type: COMPARATOR
Intervention: Conventional megavoltage x-rays (photons)
Number of subjects: 10
Study 2895630 — intervention group
Group type: EXPERIMENTAL
Intervention: Transscleral cryotherapy to the avascular retina
Number of subjects: 172
Study 2895630 — intervention group
Group type: COMPARATOR
Intervention: Untreated eyes
Number of subjects: 172
Study 1520755 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet A (animal protein diet)
Number of subjects: 8
Study 1520755 — intervention group
Group type: COMPARATOR
Intervention: Diet V (vegetable protein diet)
Number of subjects: 8
Study 718514 — intervention group
Group type: EXPERIMENTAL
Intervention: GITS 15/125 (15 mg/hr, administered twice a day)
Number of subjects: 8
Study 718514 — intervention group
Group type: COMPARATOR
Intervention: Conventional 250‐mg acetazolamide tablets
Number of subjects: 8
Study 31216955 — intervention group
Group type: EXPERIMENTAL
Intervention: Preconception counseling (six sessions of group counseling)
Number of subjects: 152
Study 31216955 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 152
Study 30830654 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX) 1200 mg orally before angioplasty
Number of subjects: 90
Study 30830654 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PTX)
Number of subjects: 90
Study 30830654 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX)
Number of subjects: 90
Study 28375887 — intervention group
Group type: EXPERIMENTAL
Intervention: Interscalene brachial plexus blockade
Number of subjects: 156
Study 28375887 — intervention group
Group type: COMPARATOR
Intervention: Intraoperative soft‐tissue infiltration of bupivacaine liposome injectable suspension
Number of subjects: 156
Study 26500462 — intervention group
Group type: EXPERIMENTAL
Intervention: High Protein group (HP) consuming >3 g/kg/d of dietary protein
Number of subjects: 48
Study 26500462 — intervention group
Group type: COMPARATOR
Intervention: Normal Protein group (NP) consuming 2 g/kg/d of dietary protein
Number of subjects: 48
Study 26500462 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (NP and HP)
Number of subjects: 48
Study 26500462 — intervention group
Group type: EXPERIMENTAL
Intervention: High Protein group (HP)
Number of subjects: 48
Study 26500462 — intervention group
Group type: COMPARATOR
Intervention: Normal Protein group (NP)
Number of subjects: 48
Study 24274431 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention using mobile device‐based clinical decision support system
Number of subjects: 15000
Study 21450630 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill training (repetitive intervals to onset of claudication pain, three times a week)
Number of subjects: 68
Study 21450630 — intervention group
Group type: COMPARATOR
Intervention: Control group (no change in physical activity)
Number of subjects: 68
Study 19709480 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromodulation (sacral neuromodulation, tibial nerve stimulation, chemical neuromodulation)
Number of subjects: 0
Study 19709480 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (behavioral modification and anticholinergic medication)
Number of subjects: 0
Study 17713332 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone treatment for 40 seconds
Number of subjects: 102
Study 17713332 — intervention group
Group type: COMPARATOR
Intervention: Air treatment for 40 seconds (Control)
Number of subjects: 102
Study 15107371 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (MTP) 10 mg intravenously plus placebo intramuscularly
Number of subjects: 336
Study 15107371 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide-pethidine (M-PET) 10 mg MTP intravenously plus 50 mg pethidine intramuscularly
Number of subjects: 336
Study 15107371 — intervention group
Group type: COMPARATOR
Intervention: Pethidine (PET) 50 mg intramuscularly plus placebo intravenously
Number of subjects: 336
Study 15107371 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLC) intramuscular and intravenous
Number of subjects: 336
Study 12269647 — intervention group
Group type: EXPERIMENTAL
Intervention: MFNS 200 microg, twice daily
Number of subjects: 967
Study 12269647 — intervention group
Group type: EXPERIMENTAL
Intervention: MFNS 400 microg, twice daily
Number of subjects: 967
Study 12269647 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 967
Study 9839094 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose (25 mg t.i.d. to 100 mg t.i.d. over 24 weeks)
Number of subjects: 0
Study 9839094 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8083795 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic Probe (E.P.)
Number of subjects: 20
Study 8083795 — intervention group
Group type: COMPARATOR
Intervention: Conventional Probe (C.P.)
Number of subjects: 20
Study 8083795 — intervention group
Group type: EXPERIMENTAL
Intervention: E.P. and C.P. used interchangeably
Number of subjects: 20
Study 8083795 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic Probe (E.P.) and Conventional Probe (C.P.)
Number of subjects: 20
Study 2910779 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarterial cis-platinum injection
Number of subjects: 9
Study 2910779 — intervention group
Group type: COMPARATOR
Intervention: Intravenous cis-platinum injection
Number of subjects: 9
Study 805475 — intervention group
Group type: EXPERIMENTAL
Intervention: Triethylenethiophosphoramide
Number of subjects: 826
Study 805475 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 826
Study 31658910 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinically diagnosed anorexia nervosa
Number of subjects: 782938
Study 31658910 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinically diagnosed bulimia nervosa
Number of subjects: 782938
Study 31658910 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic correlation between anorexia nervosa and bulimia nervosa
Number of subjects: 782938
Study 31658910 — intervention group
Group type: EXPERIMENTAL
Intervention: Unique environmental correlation between anorexia nervosa and bulimia nervosa
Number of subjects: 782938
Study 31658910 — intervention group
Group type: EXPERIMENTAL
Intervention: Overlap of anorexia nervosa and bulimia nervosa
Number of subjects: 782938
Study 30721234 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention comprising clinical guidelines, monthly prescribing review meetings, doctor‐patient communication skills training, and education materials for caregivers.
Number of subjects: 1400
Study 30721234 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 1400
Study 30721234 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention.
Number of subjects: 1400
Study 27306985 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-navigated TKA (NAV)
Number of subjects: 225
Study 27306985 — intervention group
Group type: COMPARATOR
Intervention: Conventional TKA (CON)
Number of subjects: 225
Study 27306985 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (NAV and CON)
Number of subjects: 225
Study 25869112 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Number of subjects: 120
Study 25869112 — intervention group
Group type: COMPARATOR
Intervention: Healthy Eating diet
Number of subjects: 120
Study 23913585 — intervention group
Group type: EXPERIMENTAL
Intervention: Armodafinil
Number of subjects: 0
Study 21306953 — intervention group
Group type: EXPERIMENTAL
Intervention: gemcitabine plus axitinib
Number of subjects: 632
Study 21306953 — intervention group
Group type: COMPARATOR
Intervention: gemcitabine plus placebo
Number of subjects: 632
Study 19247240 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly dressing change
Number of subjects: 81
Study 19247240 — intervention group
Group type: COMPARATOR
Intervention: Twice-weekly dressing change
Number of subjects: 81
Study 16464701 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidimensional Anxiety Scale for Children (MASC)
Number of subjects: 193
Study 16464701 — intervention group
Group type: EXPERIMENTAL
Intervention: MASC subscales and two MASC items
Number of subjects: 193
Study 16464701 — intervention group
Group type: EXPERIMENTAL
Intervention: MASC
Number of subjects: 193
Study 15031566 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 5, 10, 15 and 30 microg twice daily via the Certihaler
Number of subjects: 67
Study 15031566 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 12 microg b.i.d. via the Aerolizer
Number of subjects: 67
Study 15031566 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 11564594 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous IL-2 at either 4.5 MIU or 7.5 MIU q12h for 5 days every 8 weeks
Number of subjects: 36
Study 11564594 — intervention group
Group type: COMPARATOR
Intervention: No therapy (Control)
Number of subjects: 36
Study 9784909 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute administration of propionyl-L-carnitine (IV bolus, 30 mg/kg body weight)
Number of subjects: 30
Study 9784909 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic administration of propionyl-L-carnitine (1.5 mg/d for 1 month)
Number of subjects: 30
Study 9784909 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 30
Study 7908532 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg and 100 mg
Number of subjects: 8
Study 7908532 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol 5 mg twice daily and 15 mg twice daily
Number of subjects: 8
Study 7908532 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg
Number of subjects: 8
Study 7908532 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol 15 mg twice daily
Number of subjects: 8
Study 3198977 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiapamil (lower dose)
Number of subjects: 0
Study 3198977 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiapamil (higher dose)
Number of subjects: 0
Study 3198977 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (lower dose)
Number of subjects: 0
Study 3198977 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (higher dose)
Number of subjects: 0
Study 30392289 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple CPAP
Number of subjects: 53
Study 30392289 — intervention group
Group type: COMPARATOR
Intervention: Traditional CPAP
Number of subjects: 53
Study 27581221 — intervention group
Group type: EXPERIMENTAL
Intervention: Active NIV
Number of subjects: 54
Study 27581221 — intervention group
Group type: COMPARATOR
Intervention: Sham NIV
Number of subjects: 54
Study 24168837 — intervention group
Group type: COMPARATOR
Intervention: TDS (Text Delivery System)
Number of subjects: 150
Study 24168837 — intervention group
Group type: COMPARATOR
Intervention: T-CPI (Computer-based Programmed Instruction with Text)
Number of subjects: 150
Study 24168837 — intervention group
Group type: COMPARATOR
Intervention: V-CPI (Computer-based Programmed Instruction with Voice)
Number of subjects: 150
Study 24168837 — intervention group
Group type: COMPARATOR
Intervention: SA-CPI (Computer-based Programmed Instruction with Static Avatar and Text)
Number of subjects: 150
Study 24168837 — intervention group
Group type: COMPARATOR
Intervention: DA-CPI (Computer-based Programmed Instruction with Dynamic Avatar)
Number of subjects: 150
Study 22655053 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon-α2a 180 µg once weekly and ribavirin 800 mg daily
Number of subjects: 303
Study 21086865 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-based mentor tutor program (PMTP)
Number of subjects: 0
Study 21086865 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PMTP)
Number of subjects: 0
Study 18545197 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine L-tartrate (LCLT) 2 g/d for 23 days
Number of subjects: 9
Study 18545197 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 15954954 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 18
Study 15954954 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 18
Study 12548090 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN, 30 mg TID)
Number of subjects: 18
Study 12548090 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentaerythrityl tetranitrate (PETN, 80 mg TID)
Number of subjects: 18
Study 10526912 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified antihypertensive therapy (IT group)
Number of subjects: 91
Study 10526912 — intervention group
Group type: COMPARATOR
Intervention: Routine antihypertensive therapy (RT group)
Number of subjects: 91
Study 7574765 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial (IA) therapy
Number of subjects: 51
Study 7574765 — intervention group
Group type: COMPARATOR
Intervention: Intra-venous (IV) therapy
Number of subjects: 51
Study 7574765 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate/5‐FU (FMTX) therapy
Number of subjects: 51
Study 7574765 — intervention group
Group type: COMPARATOR
Intervention: 5‐FU/CDDP (FP) therapy
Number of subjects: 51
Study 7574765 — intervention group
Group type: EXPERIMENTAL
Intervention: FMTX therapy
Number of subjects: 51
Study 7574765 — intervention group
Group type: COMPARATOR
Intervention: FP therapy
Number of subjects: 51
Study 7574765 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial (IA) chemotherapy
Number of subjects: 51
Study 7574765 — intervention group
Group type: COMPARATOR
Intervention: Intra-venous (IV) chemotherapy
Number of subjects: 51
Study 2117055 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxacillin
Number of subjects: 356
Study 2117055 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 356
Study 7398139 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 34
Study 7398139 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 34
Study 7398139 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 31782966 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile MI (1 session via mobile phone)
Number of subjects: 300
Study 31782966 — intervention group
Group type: COMPARATOR
Intervention: In-person MI (1 session at health center)
Number of subjects: 300
Study 31782966 — intervention group
Group type: COMPARATOR
Intervention: Mobile MI (delayed by 1 month)
Number of subjects: 300
Study 29221491 — intervention group
Group type: EXPERIMENTAL
Intervention: Gantenerumab 105 mg
Number of subjects: 797
Study 29221491 — intervention group
Group type: EXPERIMENTAL
Intervention: Gantenerumab 225 mg
Number of subjects: 797
Study 29221491 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 797
Study 27397040 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy (two cycles concurrent cisplatin 50 mg/m(2) and four adjuvant cycles of carboplatin AUC 5 and paclitaxel 175 mg/m(2))
Number of subjects: 686
Study 27397040 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone (48·6 Gy in 1·8 Gy fractions five times a week)
Number of subjects: 686
Study 27397040 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy
Number of subjects: 686
Study 27397040 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 686